NEUROCRINE BIOSCIENCES INC Additional Paid in Capital, Common Stock
NEUROCRINE BIOSCIENCES INC (NBIX) had Additional Paid in Capital, Common Stock of $2.96 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-07-31
- 2026-06-30: Additional Paid in Capital, Common Stock $2.96B.
- 2026-03-31: Additional Paid in Capital, Common Stock $2.82B.
- 2025-12-31: Additional Paid in Capital, Common Stock $2.79B.
- 2025-09-30: Additional Paid in Capital, Common Stock $2.70B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $2.96B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $2.82B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $2.79B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $2.70B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $2.60B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $2.53B 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $2.55B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $2.62B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $2.56B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.50B 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $2.38B 10-K · filed 2025-02-10 | |
| 2023-09-30 | $2.31B 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $2.24B 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $2.17B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $2.12B 10-K · filed 2024-02-09 | |
| 2022-09-30 | $2.05B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $2.00B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.95B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $2.01B 10-K · filed 2023-02-09 | |
| 2021-09-30 | $1.97B 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $1.93B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.90B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.85B 10-K · filed 2022-02-11 | |
| 2020-09-30 | $1.87B 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.84B 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $1.80B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.77B 10-K · filed 2021-02-05 | $1.77B 10-K · filed 2020-02-07 |
| 2019-09-30 | $1.74B 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $1.70B 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $1.68B 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $1.66B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $1.65B 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $1.63B 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $1.61B 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $1.57B 10-K · filed 2019-02-08 | |
| 2017-09-30 | $1.55B 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $1.54B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $1.38B 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $1.37B 10-K · filed 2018-02-13 | |
| 2016-09-30 | $1.36B 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $1.36B 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $1.35B 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.34B 10-K · filed 2017-02-14 | |
| 2015-09-30 | $1.33B 10-Q · filed 2015-10-29 | |
| 2014-12-31 | $1.04B 10-K · filed 2016-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |